A Guide to the Monoclonal Antibody Production Process

The monoclonal antibody production process is essential to modern biotechnology, especially in research, diagnostics, and therapeutics. At Cell Culture Company, we support every phase of this process—from hybridoma creation to large-scale manufacturing using mammalian cell systems. Our team ensures each step produces consistent, high-quality antibodies tailored to your needs.

What Are Monoclonal Antibodies?

Monoclonal antibodies (mAbs) bind to a single, specific epitope on a target antigen. Their precision gives them significant advantages over polyclonal antibodies. These benefits include superior consistency, specificity, and reduced cross-reactivity. As a result, they are ideal tools for use in both therapeutic and diagnostic applications.

Researchers can generate monoclonal antibodies through several methods, including:

  • Hybridoma technology

  • Recombinant expression from synthetic genes

  • Recombinant expression from existing hybridomas

  • Phage display

Each approach has unique advantages depending on your goals and timeline.

Hybridoma Technology

Hybridoma production remains a cornerstone of monoclonal antibody development. This traditional technique begins with immunizing a host animal—usually a mouse—with the desired antigen. After the immune system produces antibody-generating B cells, researchers harvest these cells from the spleen and fuse them with immortal myeloma cells to create hybridomas.

Key steps include:

  • Isolating spleen-derived B cells

  • Fusing with myeloma cells

  • Screening for high-affinity clones

  • Expanding selected hybridomas in culture

  • Collecting and purifying the antibodies

Researchers typically purify mAbs using affinity chromatography, although crude supernatant can be used in some applications.

Recombinant Antibody Production from Synthetic Genes

For scalable and animal-free antibody production, recombinant methods are a strong alternative. Scientists begin by synthesizing DNA sequences that encode the desired antibody. They then insert these sequences into expression vectors, which are introduced into mammalian host cells.

This method offers several key benefits:

  • No reliance on animals

  • Elimination of batch-to-batch variation

  • Complete control over antibody structure and subclass

Because this approach allows engineering at the genetic level, researchers can enhance antibody stability, binding, or effector function.

Recombinant Production from Existing Hybridomas

If you already have a hybridoma but want better reproducibility or a more controlled expression system, recombinant conversion is a powerful option. Scientists extract and sequence the genes encoding the heavy and light antibody chains, then express them in a stable mammalian system.

This transition ensures long-term production continuity and improves consistency across batches.

Phage Display Technology

Phage display bypasses the need for immunization altogether. Researchers construct libraries of antibody fragments displayed on the surfaces of bacteriophages. They then select phages that bind tightly to a specific antigen through several rounds of screening and enrichment.

This in vitro system is especially useful when working with toxic, unstable, or non-immunogenic targets.

Your Monoclonal Antibody Production Process Partner

Whether you need traditional hybridoma services or recombinant development, Cell Culture Company offers tailored solutions at every scale. Our services include:

  • Antibody production from existing hybridomas (we do not work with animals)

  • Recombinant mAb development from sequence or hybridomas

  • Small- to large-scale mAb production in mammalian systems

  • Downstream purification, quality control, and aliquoting

We partner with biotech, academic, and diagnostic organizations to deliver reproducible, high-quality monoclonal antibodies. To learn more or get a quote, contact us today or call 763.786.0302.

Cell Culture Company logo